CPX‐351 (Vyxeos(®)) can cause severe rash in acute myeloid leukemia—A case report

CPX‐351, a promising new agent for patients with treatment‐related and secondary acute myeloid leukemia can lead to a severe whole‐body rash. Although severe side effects are rare, treatment should be carefully monitored at specialized centers.

Detalles Bibliográficos
Autores principales: Urbantat, Ruth M., Popper, Valentin, Menschel, Elisabeth, Pfeilstöcker, Michael, Forjan, Ernst, Nader, Alexander, Sieghart, Catherine R., Keil, Felix, Koller, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077323/
https://www.ncbi.nlm.nih.gov/pubmed/33936618
http://dx.doi.org/10.1002/ccr3.3909
_version_ 1783684860337979392
author Urbantat, Ruth M.
Popper, Valentin
Menschel, Elisabeth
Pfeilstöcker, Michael
Forjan, Ernst
Nader, Alexander
Sieghart, Catherine R.
Keil, Felix
Koller, Elisabeth
author_facet Urbantat, Ruth M.
Popper, Valentin
Menschel, Elisabeth
Pfeilstöcker, Michael
Forjan, Ernst
Nader, Alexander
Sieghart, Catherine R.
Keil, Felix
Koller, Elisabeth
author_sort Urbantat, Ruth M.
collection PubMed
description CPX‐351, a promising new agent for patients with treatment‐related and secondary acute myeloid leukemia can lead to a severe whole‐body rash. Although severe side effects are rare, treatment should be carefully monitored at specialized centers.
format Online
Article
Text
id pubmed-8077323
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80773232021-04-29 CPX‐351 (Vyxeos(®)) can cause severe rash in acute myeloid leukemia—A case report Urbantat, Ruth M. Popper, Valentin Menschel, Elisabeth Pfeilstöcker, Michael Forjan, Ernst Nader, Alexander Sieghart, Catherine R. Keil, Felix Koller, Elisabeth Clin Case Rep Case Reports CPX‐351, a promising new agent for patients with treatment‐related and secondary acute myeloid leukemia can lead to a severe whole‐body rash. Although severe side effects are rare, treatment should be carefully monitored at specialized centers. John Wiley and Sons Inc. 2021-02-12 /pmc/articles/PMC8077323/ /pubmed/33936618 http://dx.doi.org/10.1002/ccr3.3909 Text en © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Urbantat, Ruth M.
Popper, Valentin
Menschel, Elisabeth
Pfeilstöcker, Michael
Forjan, Ernst
Nader, Alexander
Sieghart, Catherine R.
Keil, Felix
Koller, Elisabeth
CPX‐351 (Vyxeos(®)) can cause severe rash in acute myeloid leukemia—A case report
title CPX‐351 (Vyxeos(®)) can cause severe rash in acute myeloid leukemia—A case report
title_full CPX‐351 (Vyxeos(®)) can cause severe rash in acute myeloid leukemia—A case report
title_fullStr CPX‐351 (Vyxeos(®)) can cause severe rash in acute myeloid leukemia—A case report
title_full_unstemmed CPX‐351 (Vyxeos(®)) can cause severe rash in acute myeloid leukemia—A case report
title_short CPX‐351 (Vyxeos(®)) can cause severe rash in acute myeloid leukemia—A case report
title_sort cpx‐351 (vyxeos(®)) can cause severe rash in acute myeloid leukemia—a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077323/
https://www.ncbi.nlm.nih.gov/pubmed/33936618
http://dx.doi.org/10.1002/ccr3.3909
work_keys_str_mv AT urbantatruthm cpx351vyxeoscancausesevererashinacutemyeloidleukemiaacasereport
AT poppervalentin cpx351vyxeoscancausesevererashinacutemyeloidleukemiaacasereport
AT menschelelisabeth cpx351vyxeoscancausesevererashinacutemyeloidleukemiaacasereport
AT pfeilstockermichael cpx351vyxeoscancausesevererashinacutemyeloidleukemiaacasereport
AT forjanernst cpx351vyxeoscancausesevererashinacutemyeloidleukemiaacasereport
AT naderalexander cpx351vyxeoscancausesevererashinacutemyeloidleukemiaacasereport
AT sieghartcatheriner cpx351vyxeoscancausesevererashinacutemyeloidleukemiaacasereport
AT keilfelix cpx351vyxeoscancausesevererashinacutemyeloidleukemiaacasereport
AT kollerelisabeth cpx351vyxeoscancausesevererashinacutemyeloidleukemiaacasereport

Ejemplares similares